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ABSTRACT
The Effect of Non-Marine vs. Marine Sources of the Omega-3 Fatty Acids, DHA and EPA,
on Serum Lipoproteins
Mary C. Rodavich
Background: Fish oil (FO) is a marine source of n-3 fatty acids, eicosapentaenoic acid (EPA)
and docosahexanaenoic acid (DHA), and has been shown to improve heart health.
Objective: The purpose of this study was to determine the cardiovascular effects of non-marine
sources of n-3 fatty acids, algae oil (AO) and yeast oil (YO), as compared to fish oil (FO).
Methods: Male ICR mice (8 wk old, n=100) were randomly assigned to dietary treatment
groups: soy oil (SO; 0 g/kg DHA or EPA), FO (7.03 g/kg DHA + 12.64 g/kg EPA), AO (7.03
g/kg DHA + 0.13 g/kg EPA), YO (0.018 g/kg DHA + 12.64 g/kg EPA), or AO+YO (7.05 g/kg
DHA + 12.77 g/kg EPA) for 2 or 4 wks. Serum triglycerides (TG), total cholesterol (TC), and
HDL-cholesterol (HDLC) were measured and non-HDL cholesterol (NHDLC) was calculated.
Liver DHA and EPA concentration were determined. The liver mRNA expression was
determined by real time RT-PCR for the following genes: apolipoprotein B100 (ApoB100), acylCoA:cholesterol acyltransferase (ACAT), diglyceride acyltransferase (DGAT), low-density
lipoprotein receptor (LDLR), and 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR). P <
0.05 is considered significant.
Results: The FO diet lowered all fractions of serum lipids and was the only diet to reduce TG.
YO, alone and in combination with AO, reduced TC and NHDLC similar to FO at 4 wks. At
both time points, FO-fed mice had significantly greater EPA and DHA incorporation into the
liver than all other diet treatments. At both time points, SO-fed mice had significantly greater
hepatic arachidonic acid (C20:4) concentrations than all other diet treatments. At both time
points, FO-fed mice had significantly greater n-3 to n-6 ratios compared to all other diet
treatments. There were no significant differences between any of the diet treatments at any time
points in hepatic mRNA expression of ApoB100, ACAT, DGAT, and LDLR. However, at both
time points the FO-fed mice had significantly down-regulated HMGCR expression compared to
the SO-fed mice.
Conclusion: In conclusion, it appears that FO supplementation may be more beneficial for
cardiovascular health due to its ability to decrease serum lipids and TGs, incorporate EPA and
DHA into the liver, obtain a greater n-3 to n-6 ratio, and lower hepatic HMGCR mRNA
expression.
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CHAPTER 1
REVIEW OF LITERATURE

1

INTRODUCTION
There has been a vast amount of scientific and medical interest in the beneficial effects of
long chain omega-3 polyunsaturated fatty acids (n-3 LC-PUFAs) on the risk for cardiovascular
disease (CVD). The n-3 LC-PUFAs, eicosapentaenoic acid (EPA; 20:5n-3) and
docosahexaenoic acid (DHA; 22:6n-3), have been associated with a decreased risk of CVD
incidence and mortality (1). This is significant in the western world because CVD is the leading
cause of death in the United States (2). There are several proposed mechanisms whereby n-3 LCPUFAs reduce the risk of heart disease. Omega-3 fatty acids have been found to decrease plasma
triglyceride levels, mildly lower blood pressure, and to have anti-inflammatory effects (1).
Omega-3’s are thought to lower triglyceride (TG) levels by decreasing endogenous VLDL
secretion by the liver because they may not be the preferred substrate of the enzyme,
diacylglycerol O-acyltransferase (DGAT), or omega-3 PUFAs may alter transcription factors
that control lipogenesis (3).
Consumption of a high ratio of omega-6 to omega-3 fatty acids has been shown to be proinflammatory and increase the risk of CVD. This is because omega-6 and omega-3 fatty acid
metabolism compete for the same rate limiting enzyme (Δ6-desaturase) (4). The precursor for
omega-3 PUFA is alpha-linolenic acid (ALA) and is found primarily in plant-based foods and
oils such as rapeseed and soybean oils, green leafy vegetables, and nuts. ALA is converted to
EPA by the introduction of a double bond by Δ6-desaturase to stearidonic acid (18:4); this is the
rate limiting step of the omega-3 pathway. Then, two carbons are added by elongase, followed
by the action of Δ5-desaturase to form EPA (20:5). The next step is the conversion of EPA to
DHA. This involves the addition of two carbons by elongase followed by the addition of another
two carbons by elongase, resulting in tetracosapentaenoic acid (24:5). The next step is
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desaturation by Δ6-desaturase to form a double bond, followed by β-oxidation which loses two
carbons in order to form DHA (22:6). The chemical structures of EPA and DHA are presented
in Figure 1. The conversion of ALA to EPA and ALA to DHA is not very efficient by the human
body. The body only converts between approximately 8-10% of ALA to EPA (with conversion
generally higher in women, thought to be due to estrogen levels) and 0.05% to 4% of ALA to
DHA (5). Therefore, it is more efficient to consume those PUFA’s as whole sources of EPA and
DHA rather than through ALA.
The n-3 LC-PUFAs are most commonly consumed through sources of marine origin,
such as fatty, cold water fish. Common marine sources of omega-3 fatty acids include sardines in
sardine oil, Atlantic mackerel, herring, Chinook salmon, anchovies, and Atlantic salmon. Nonmarine or alternative sources of n-3 LC-PUFAs include microalgae or algae and yeast (4). There
is a vast amount of evidence supporting the benefits of fish oil, which is high in both EPA and
DHA, on CVD risk factors. However, the specific contributions of EPA and DHA to these
benefits are mostly unknown. The objective of this paper is to examine the literature on nonmarine and marine sources of EPA and/or DHA and its effects on body weight, lipids, and
lipoproteins.

I.

LIPID AND LIPOPROTEIN METABOLISM
Lipoproteins are lipids bound to proteins and transported through the blood. Varying

amounts of triglyceride, cholesterol, phospholipid, and protein determines the class or type of
lipoprotein. These lipoproteins are very-low density lipoprotein (VLDL), low-density lipoprotein
(LDL), and high density lipoprotein (HDL). Clinically, total cholesterol measures cholesterol
attached on all lipoprotein subfractions (VLDL, LDL, and HDL).
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High TG levels have been shown to be associated with increased CVD risk (1). TG is an
ester formed from glycerol and three fatty acids and is the major storage form of lipids and the
primary lipid form consumed in the diet. Diglyceride acyltransferase (DGAT) catalyzes the
addition of a fatty acyl chain to a diacylglycerol, which is the rate-limiting step in TG synthesis
(6).
Population studies have shown that high cholesterol levels are associated with an
increased risk of CVD, stroke, and death. Human studies have shown that a 10% reduction in
total cholesterol decreases the risk for CVD by 30% (4). Dietary cholesterol can be consumed
through the diet or cholesterol can be produced from acetyl CoA by most tissues in the body via
de novo cholesterol synthesis. However, the liver is the major site of cholesterol synthesis. There
are at least 26 steps in the synthesis of cholesterol, refer to Figure 2 (7). HMG-CoA reductase is
the rate limiting enzyme in cholesterol synthesis, reducing 3-hydroxy-3-methylgluaryl CoA
(HMG-CoA) to mevalonate (6). HMG-CoA reductase is located in the smooth endoplasmic
reticulum and is an important point for the regulation of cholesterol synthesis. HMG-CoA
reductase activity is mediated by phosphorylation in response to glucagon (decreases cholesterol
synthesis) and dephosphorylation in response to insulin (promoting cholesterol synthesis),
respectively (8). Cholesterol biosynthesis indirectly requires the transcription factors, sterol
regulatory element-binding proteins (SREBPs). There are three SREBP isoforms: SREBP1a,
SREBP1c, and SREBP2. The predominant isoform in rodent and mammalian and rodent livers is
SREBP1c. SREBP1c induces the transcription of a variety of genes involved in lipogenesis and
SREBP2 is involved in cholesterol synthesis (9,10).
LDL is the primary carrier of cholesterol in the blood, from which 60% is taken up by
LDL receptors in the liver, adrenals, and various other tissues. The number and activity of LDL
4

receptors is a determinant of the level of LDL-C in the blood (6). When LDL binds to its LDL
receptor, endocytosis is initiated and the LDL as well as the receptor are taken into the cell
(known as receptor-mediated endocytosis). The LDL receptors then return to the surface of the
cell and the cholesteryl esters are hydrolyzed, thus releasing cholesterol and fatty acids into the
cytosol (8).
ACAT (acyl CoA: cholesteryl acyl transferase) is located in the endoplasmic reticulum
and forms cholesterol esters from cholesterol by transferring a fatty acid from coenzyme A to the
hydroxyl group of cholesterol (6). Cholesteryl esters are either stored in the liver or transported
by lipoproteins to other tissues throughout the body. High levels of ACAT signal cholesterol
esterification (8). Lecithin:cholesterol acyltransferase (LCAT) forms cholesteryl esters from free
cholesterol and lecithin, which allows a newly formed HDL precursor particle to mature to a full
HDL lipoprotein. These cholesterol esters are then transported to the liver bound to HDL,
hydroylzed by cholesteryl esterase, and excreted in the bile. Because HDL-C is the major
component of this process, known as reverse cholesterol transport, high HDL-C levels are
associated with a decreased risk of CVD. The release of cholesterol esters also decreases HMGCoA reductase activity, increases ACAT activity, and decreases the number of LDL receptors to
reduce the uptake of cholesterol from the blood.
These lipoprotein factors are influenced by n-3 LC-PUFAs. This paper will review the
effect of different sources of n-3 LC-PUFAs on these factors starting with the most popular
source, fish oil, followed by algae oil and yeast oil.
II.

MARINE VS. NON-MARINE SOURCES OF OMEGA-3
SUPPLEMENTATION
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A. Fish Oil Supplementation
There is a vast amount of scientific evidence from animal and human studies that have
shown the beneficial effects of fish oil consumption and/or supplementation on cardiovascular
health. It is well established in the literature that fish and fish oil consumption at 1-2 g/day have
been shown to decrease the risk of CVD. The general recommendation is 0.3-0.5 g from EPA
and DHA and 0.8-1.1 g ALA (1). A list of the types of marine and non-marine sources of omega3 fatty acids are presented in Table 1.
As a marine source, fish oil contains high concentrations of both EPA and DHA. In a
meta-analysis by Konig et al., eight studies were analyzed to determine the relative risk of fish
consumption on non-fatal myocardial infarction (MI) and CVD mortality. After relative risks
were averaged and weighted, results found that consumption of fish, even in small quantities, by
individuals that had no pre-existing CVD was associated with a 17% reduction in CVD risk.
Also, a 3.9% reduction in risk was also associated with each additional serving of fish per week
(11).
Rokling-Andersen et al. studied the effects of marine omega-3 fatty acids on 20 male
Wistar rats for 7 weeks. The rats were randomly assigned into two groups, ten rats per group.
One group was fed 19.5% lard and the other was fed an omega-3 rich diet containing 10.4%
Triomar (a fish oil consisting of 30% EPA and 18% DHA) and 9.1% lard. The authors measured
weight gain, plasma lipid concentration, the expression of various genes, and visceral and
adipose tissue using magnetic resonance imaging (MRI) and dissection. Results showed that the
fish oil group had significantly lower blood lipid concentration. TG were 56% lower (p<0.001),
phospholipids were 41% lower (p<0.001), and total cholesterol was 40% (p=0.05) lower than the
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lard group. Magnetic resonance imaging showed that adipose tissue was also significantly
decreased in the fish oil group. Visceral adipose depots (mesenteric, perirenal and epididymal)
were decreased 35% (p<0.05), 44% (P<0.01) and 32% (P<0.01) respectively compared to the
lard group. DGAT mRNA expression was also significantly reduced (P<0.05) in the perirenal
and epididymal fat depots in the fish oil group. Therefore, fish oil supplementation in male rats
showed improved lipoprotein levels and slowed weight gain (12). However, discrepancies
between MRI and dissection weight and volume of mesenteric fat may indicate the difficulty of
these types of measurements.
Fickova et al. also studied the effects of omega-3 supplementation on male Wistar rats.
However, in comparison to the 7-week study by Rokling-Andersen et al., this was a very short
term study conducted over only one week. Rats were randomized into one of two diet treatments
consisting of 40.7% lipid content; sunflower oil (omega-6 PUFA) or fish oil (Max EPA, omega-3
PUFA). The fish oil diet consisted of 16.3% EPA 9.3% DHA. Measurements included
epididymal adipocyte size and plasma lipoproteins. Results found that the fish oil group gained
significantly less weight (21.3 +1.1 g vs 29.1 + 1.3 g, p<0.001), had significantly smaller adipose
tissue mass (1.97 + 0.1 vs 2.45 + 0.1 g, p<0.02) and had significantly smaller adipocytes (67.0 +
2.4 µm vs 73.6 + 1.7 µm, p<0.05) than the omega-6 group. The fish oil group also had
significantly lower serum TG (1.26 + 0.1 mmol/L vs 1.70 + 0.1 mmol/L, p<0.005), total
cholesterol (0.81 + 0.06 mmol/L vs 1.45 + 0.09 mmol/L, p<0.005), and cholesterol esters (0.45 +
0.04 vs 0.91 mmol/L + 0.07 mmol/L, p<0.02) than the omega-6 PUFA group. The results of this
study support the benefits of fish oil on weight gain and improved lipoprotein levels. However,
the diets were very high in lipid content (40.7%) and may have been a contributing factor to the
results of supplementation over such a short period of time of only one week (13).
7

In a human study, 65 subjects (24 men and 41 women) were randomized into one of four
treatment groups, fish oil (FO), fish oil plus exercise (FOX), soy oil (SO, control), soy oil plus
exercise (SOX). Participants consumed 6 capsules per day of either soy oil or fish oil (tuna
source) for 12 weeks. One fish oil capsule contained 26% DHA and 6% EPA in each 1-g
capsule. The exercise regimen consisted of running or walking 3 times/week for 45 minutes at
75% of their age-adjusted maximum heart rate. Results found that this modest exercise
intervention did not produce any significant effects. Fish oil supplementation, however,
significantly reduced TG by 14% (p<0.05) and significantly increased HDL-C by 10% (p<0.05)
from baseline compared to the SO group. DEXA analysis found fat mass was significantly
reduced in both the FO (p=0.043) and FOX (p=0.005) groups (14). Therefore, evidence shows
that fish oil supplementation in human studies improved CVD lipid risk factors as well as
decreases body fat.
There are some safety considerations with the consumption of fish and/or fish oil
supplements. Fresh water and ocean fish may have levels of methyl-mercury, polychlorinated
biphenyls (PCBs), dioxins, and other environmental contaminants (1). These levels become
more concentrated in the marine food chain, with greater concentrations in the larger, dominant,
older, and more predatory fish. Contaminants can also accumulate to higher levels in individuals
who consume fish on a frequent basis. The Federal Drug Administration (FDA) concluded that
healthy individuals (other than pregnant women) can consume up to 7 oz. of fish per week with
mercury levels averaging 1 ppm and 14 oz per week of fish per week with mercury levels
averaging 0.5 ppm. Higher mercury levels (1 ppm) are found in shark, swordfish, king mackerel,
and tilefish and lower levels (0.5 ppm) are found in fresh tuna, orange roughy, marlin, and red
snapper (1). Therefore, there are several benefits to fish consumption in terms of high EPA and
8

DHA content. However, there are some safety considerations that are necessary in choosing
marine sources of n-3 LC-PUFAs, which may be one of many reasons an individual would
choose a non-marine source. Lastly, an individual may choose not to consume a fish oil
supplement due to following a vegan diet or a vegetarian diet with the exclusion of fish.
B. EPA versus DHA-rich Fish Oil Supplementation
There have also been several studies examining the effects of purified EPA and DHA
provided as fish oil ethyl esters. Whereas, algae oil and yeast oil examine the effects of DHA
and EPA alone from non-marine sources, fish oil ethyl esters study the effects of DHA and EPA
alone from marine sources. These studies are of importance in order to observe any differences
in EPA and DHA supplementation on serum lipids.
Mori et al. studied the independent effects of EPA and DHA on serum lipids and body
weight on 59 overweight, mildly hyperlipidemic men. Participants were randomly assigned by
age and BMI to receive one of three diets, 4 g/day of purified EPA ethyl ester, DHA ethyl ester,
or olive oil ethyl ester (placebo), for six weeks. Throughout the six weeks, subjects were
instructed to maintain their usual diets, alcohol intakes, physical activity, and to not make any
lifestyle changes. Measurements included serum total cholesterol, TG, LDL-C, LDL particle
size, and HDL-C. Results found that neither EPA nor DHA significantly decreased serum total
cholesterol levels. Fasting serum TG decreased significantly by 18.4% in the EPA group
(p=0.012) and by 20% in the DHA group (p=0.003) compared to placebo. Serum LDL-C
increased significantly by 8% in the DHA group (p=0.019) and also significantly increased LDL
particle size (0.25 + 0.08 nm, p=0.002), but there were no significant effects in the EPA group.
The authors attribute the increased LDL-C levels with DHA supplementation because omega-3
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fats reduce VLDL synthesis and/or secretion. This results in smaller VLDL particles, which are
more readily converted to LDL. DHA supplementation also increased LDL particle size, which
can be contributable to decreased CVD risk and may be a more favorable finding. There were no
significant changes in HDL-C, but the EPA group experienced a 3% decrease in HDL-C whereas
the DHA group experienced a 3% increase in HDL-C. Therefore, this study found that both
purified forms of EPA and DHA reduce serum TG, but have differential effects on LDL-C and
HDL-C (15).
In another study on purified EPA and DHA ethyl esters, Grimsgaard et al. randomly
assigned 234 healthy men to one of three diet treatments. Subjects received dietary supplements
as capsules of either 4 g of 95% EPA ethyl ester/day, 4 g of 90% DHA ethyl esterday, or 4 g/day
of corn oil as the placebo group for seven weeks. Measurements included body weight, total
cholesterol, LDL-C, apolipoprotein B, and total cholesterol:HDL-C ratio. Results showed there
were no differences in body weight or apolipoprotein B concentrations after the intervention
between any of the groups. Both EPA and DHA groups had significantly reduced TG levels
compared to placebo (21% and 26%, respectively, p=0.0001). However, the difference between
the DHA and EPA groups was not significant (p=0.14). In the EPA group, total cholesterol
decreased significantly by 0.14 mmol/L (p<0.05) from baseline. This decrease was significant
compared to the DHA group and placebo group (p=0.04 and p=0.004, respectively). In the DHA
group, HDL-C significantly increased by 0.06 mmol/L (p<0.001) from baseline. This increase
was significantly different from both EPA and placebo groups (p=0.009 and p=0.0005,
respectively). Also, both EPA and DHA groups had significantly decreased total
cholesterol:HDL ratios compared to placebo (p=0.007 and p=0.0006, respectively). This study
agreed with much of the literature that both EPA and DHA lower TG concentrations, but this is
10

one of the first to show a more pronounced effect in DHA supplementation. This study also
observed differential effects of EPA and DHA on total cholesterol and HDL-C (16).
Arai et al. studied the effects of EPA or DHA-rich fish oil on lipid metabolism of 20
female KK mice (aged 5 weeks). Mice were randomized into one of four diet treatments
consisting of 25% lipid for 8 weeks: either lard/safflower oil (Lard/SO, control), EPA-rich fish
oil (20% EPA and 13% DHA), or DHA-rich fish oil (7% EPA and 24% DHA). Results showed
that weight gain was significantly lower in both the EPA and DHA-rich fish oil groups compared
to the Lard/SO group (p<0.05). There was no significant difference between the fish oil groups.
Liver weight was also significantly less in both EPA and DHA groups than the Lard/SO group
(1.36 + 0.14 g and 1.70 + 0.29 g, respectively, p<0.05). White adipose tissue (WAT) weight was
also significantly decreased in both the EPA and DHA groups compared to the control, with a
greater reduction in the EPA group compared to the DHA group (3.02 + 0.16 g vs. 3.64 + 0.33 g,
p<0.05). Contrary to many other studies, there was no difference in serum TG between the
groups. Total cholesterol decreased significantly for both EPA and DHA groups compared to
the control group (53 + 4 mg/dL and 73 + 12 mg/dL, respectively, p<0.05). In the EPA and
DHA groups, there were significant decreases (p<0.05) in mRNA levels of HMG-CoA reductase
(79% and 53%, respectively) and LDL receptors (67% and 48%, respectively). Thus, this study
showed that both EPA and DHA-rich fish oils are successful at decreasing weight gain, body fat,
and improving serum lipids in mice, however EPA showed more pronounced and beneficial
effects. Also, the authors used a very small sample size, with only five mice per diet. A larger
number of subjects could have increased the reliability of this study (17).
C. Algae Oil Supplementation
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Non-marine or non-fish derived algae oil is composed of high DHA concentrations, with
low EPA concentrations (18). Because algal DHA is grown in the laboratory, it is essentially
free of contaminants typically found in ocean fish, such as methyl-mercury, dioxins, and
polychlorinated biphenyls. Algae oil is also being used extensively as a food additive. In a metaanalysis of fifteen human studies, supplementation of 1-2 g of non-fish derived algae oil
decreased TG 15-20% compared to baseline levels (r2=0.25, p<0.05). Algae oil has also been
shown to significantly increase HDL-C levels and decrease LDL-C levels from baseline (18).
Therefore, it is important to study the effects of algae oil supplementation on cardiovascular risk
factors.
Two recent studies at West Virginia University compared the effects of fish oil or nonmarine algae oil on male ICR mice for two or four weeks. In the first study, the mice (aged 10
weeks) were randomized by weight into one of seven diets consisting of 12% lipid; a soy oil diet
that contained no DHA (control), 5 g/kg or 10g/kg DHA from FO (FO-5 and FO-10), 5 g/kg or
10 g/kg DHA from AO (AO-5 or AO-10), or 5 g/kg or 10 g/kg from an algal biomass (AB-5 and
AB-10). Results found at two weeks, only FO-10 mice had significantly reduced TG, total
cholesterol, and LDL-C. At four weeks, FO-5 and AO-10 mice had significantly lower serum
TG, total cholesterol, and LDL-C (p<0.01). At four weeks, there were no significant differences
in body weight between the groups, but FO fed mice tended to be leaner than AO fed mice
(p=0.06). Therefore, algae oil was not as effective as fish oil at reducing body fat, serum TG,
and total cholesterol in mice (19).
In a second similar study, male ICR mice (aged 9 weeks) were fed either a fish oil or
algae oil diet consisting of 12% lipid for 2 or 4 weeks. Mice were randomized by weight into
one of five diets: 0 g/kg DHA (SO), 10 g/kg DHA (FO or AO-10), 20 g/kg DHA (AO-20), 35
12

g/kg DHA (AO-35), or 50 g/kg DHA (AO-50). Results found that at two weeks, the FO-fed
mice and all AO-fed mice had significantly lower serum TG and total cholesterol levels
(p<0.05). At four weeks, however, only FO-fed mice and higher doses of AO-fed mice (AO-35,
AO-50) significantly reduced total cholesterol (p<0.001). Therefore, algae sources were less
effective than fish oil at reducing body fat, serum TG, and total cholesterol in mice. This may be
due to the fact that greater doses of algae oil DHA concentrations were required in order to
obtain equal liver and adipose tissue DHA concentrations as mice fed the fish oil. Also, algae oil
only reduced serum TG and total cholesterol levels at doses that resulted in more than four times
the adipose tissue DHA concentration (20).
Conquer and Holub compared algae oil supplementation to placebo (corn oil) in 12 male
and 12 female vegetarians for 6 weeks. The algae oil contained 39% DHA (no EPA was
detected). Measurements at week 3 and week 6 included total cholesterol, LDL-C, HDL-C, TG,
total cholesterol:HDL ratio, and LDL:HDL ratio. Results showed that there were no significant
differences between groups in total cholesterol and LDL-C levels. However, the algae oil group
had significant decreases (p<0.05) in TG levels at week 3 and week 6 (22% and 16%,
respectively), and showed significant decreases (p<0.05) in total cholesterol:HDL ratio and
LDL:HDL ratio (16% and 22%, respectively). These ratios are better predictors of CVD
compared to total cholesterol and LDL-C levels alone (21). Therefore, algal oil supplementation
was beneficial, but no direct comparison to fish oil was made.
D. Yeast Oil Supplementation
Non-marine derived yeast oil is comprised mainly of high EPA concentrations, with very
little DHA concentrations. Yeast oil (YO) is new on the market and little research has been

13

conducted on this particular PUFA source. Yeast oil is of scientific interest because it is
important to examine the effects of a new vegetarian source of EPA on body weight and serum
lipids. Only two studies have been published on the effects of YO on rats for 28 days and 90
days. YO is derived from a strain of yeast called Yarrowia lipolytica, which was modified to
produce high EPA levels. The oil is comprised of 34-60% EPA that was produced through a
multi-step fermentation process.
In a 28-day toxicity study of yeast oil, male and female Sprague-Dawley rats (aged 7
weeks) were randomized into and fed one of five diets by oral gavage. Fifteen rats each were
randomized into one of five diets; olive oil (control), low EPA YO (325 mg/kg bw), medium
EPA YO (650 mg/kg bw), high EPA YO (976 mg/kg bw), and a fish oil diet (from sardines and
anchovies, 513 mg/kg EPA). Results found that liver weight significantly increased in both
males and females in the medium EPA, high EPA, and fish oil groups (p<0.05). There were no
significant changes in body weight in any of the groups and results indicated no adverse
toxicological effects (22).
In a 90-day toxicity study of yeast oil, 20 male and 20 female Sprague-Dawley rats were
randomized into and fed one of five diets and fed by oral gavage. The dietary treatment groups
were olive oil (control), low EPA YO (98 mg/kg), medium EPA YO (488 mg/kg EPA), high
EPA YO (976 mg/kg EPA), and a fish oil diet (from sardines and anchovies, 513 mg/kg EPA).
Results showed no differences between groups on body weight or body weight gain. In males,
total cholesterol was significantly less (p<0.05) at all times points in the medium EPA group (7987% of control) and high EPA groups (62-72% of control). Non-HDL was significantly less
(p<0.05) in the medium EPA group (72-81% of control) and high EPA group (51-60% of
control). In females, total cholesterol was also significantly reduced at every time point in the
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medium EPA group (82-85% of control) and high EPA group (51-60% of control). Non-HDL
was significantly lower in the medium EPA group (74-78% of control) and high EPA group (6070% of control). However, liver weights were significantly increased (p<0.05) in males in the
high EPA group as well as in females in the medium and high EPA groups. The authors reported
pale livers during necropsy in males, but state the increase in liver has been reported in similar
studies of rats given similar doses of omega-3 fatty acids (EPA and/or DHA). Also, HDL-C was
significantly reduced (p<0.05) in males in the high EPA YO group (76-81% of control) and the
FO groups (76-78% of control) at the 3 and 7 week time points, but there was no significant
difference in HDL-C at the end of the 90-day study. There were no reductions in HDL-C in
female rats.
Overall, the authors concluded that the yeast oil produced little adverse effects and no
toxicity effects. There were also more pronounced effects on males compared to females. Also,
higher dosages of YO were required in order to find significant effects on blood lipid levels. In
addition, the maximum recommended dose of EPA and DHA is 2 g per day, equivalent to 29
mg/kg body weight for a 70 kg adult. The highest EPA dosage consumed in this study (978
mg/kg) was nearly 34 times the EPA dosage that would be consumed by individuals as a dietary
supplement (23).
From the limited publications on yeast oil supplementation, it appears it may have some
health benefits. Further research is needed in order to better determine and understand the
physiological effects of yeast oil on humans.
III.

OVERALL CONCLUSION
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In conclusion, n-3 LC-PUFAs have been shown to reduce weight gain, the risk of heart
disease, TG, total cholesterol, LDL-C, and increase HDL-C. Many studies have shown that both
EPA and DHA in the form of algae oil, yeast oil, or purified fish oil EPA and DHA ethyl esters
have a hypotriglyceridemic effects. Algae oil has been shown to have differential effects on
LDL-C, increase HDL-C, and decrease total cholesterol:HDL ratio and LDL:HDL ratio.
However, algae may not be as effective as fish oil indicated by two studies in mice (19,20).
DHA-rich fish oil provided as ethyl esters may increase LDL-C and cholesterol, but may also
increase HDL-C. Also, EPA-rich fish oil has been shown to lower cholesterol and decrease
WAT. Yeast oil, a new dietary supplement on the market, is comprised mainly of EPA, has been
found to be safe to use. Few studies have examined yeast oil supplementation, but a current
study has shown to reduce total cholesterol and non-HDL cholesterol. However, the current
research study is novel, has yet to be performed in previous literature, and will examine the
effects of yeast oil plus algae oil supplementation compared to fish oil.
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ABSTRACT
Fish oil (FO) is a marine source of the omega-3 fatty acids, eicosapentaenoic acid (EPA)
and docosahexanaenoic acid (DHA), and has been shown to improve heart health. However, the
effects of non-marine sources of omega-3 fatty acids are not well known. Male ICR mice (8 wk
old, n=100) were randomly assigned to dietary treatment groups: soy oil (SO; 0 g/kg DHA or
EPA), FO (7.03 g/kg DHA + 12.64 g/kg EPA), AO (7.03 g/kg DHA + 0.13 g/kg EPA), YO (0.018
g/kg DHA + 12.64 g/kg EPA), or AO+YO (7.05 g/kg DHA + 12.77 g/kg EPA) for 2 or 4 wks.
Serum triglycerides (TG), total cholesterol (TC), and HDL-cholesterol (HDLC) were measured
and non-HDL cholesterol (NHDLC) was calculated. Liver fatty acids were determined by gas
chromatography. The liver mRNA expression was determined by real time RT-PCR. P < 0.05 is
considered significant. The FO diet lowered all fractions of serum lipids and was the only diet to
reduce TG. YO, alone and in combination with AO, reduced TC and NHDLC similar to FO at 4
wks. At both time points, FO-fed mice had significantly greater hepatic concentrations of EPA,
DHA, and the omega-3 to omega-6 ratio. There were no significant differences between any of
the diet treatments at either time point in hepatic mRNA expression of apolipoprotein B100
(ApoB100), acyl-CoA:cholesterol acyltransferase (ACAT), diglyceride acyltransferase (DGAT),
or low-density lipoprotein receptor (LDLR). At both time points FO-fed mice had significantly
less 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR) expression compared to SO-fed
mice. In conclusion, it appears that FO supplementation may be more beneficial in lowering
serum lipoproteins than non-marine sources.
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I.

INTRODUCTION

There has been a vast amount of scientific and medical interest in the beneficial health
effects of long chain omega-3 polyunsaturated fatty acids (n-3 LC-PUFAs), particularly
eicosapentaenoic acid (EPA; 20:5n-3) and docosahexaenoic acid (DHA; 22:6n-6). Omega-3 LCPUFAs have been associated with reduced inflammation and a decreased risk of cardiovascular
disease (CVD) incidence and mortality (1). Fish and fish oil (FO) consumption at 1-2 g/day have
been shown to decrease the risk of CVD (1). The general recommendation is for 0.3-0.5 g from
EPA and DHA and 0.8-1.1 g from α-linolenic acid (ALA) (1). As a marine source, fish oil
contains high concentrations of both EPA and DHA. However, the specific contributions of EPA
and/or DHA on CVD risk are less well understood. An individual may also choose to exclude
fish and fish products from their diet for various safety, sustainability, ethical, and personal
reasons. Therefore, non-marine sources of n-3 LC-PUFAs, such as microalgae (or algae) and
yeast, may be a valuable alternative (4).
Non-marine or non-fish derived algae oil (AO) is composed of high DHA concentrations,
with very low EPA concentrations. In a meta-analysis of fifteen human studies, supplementation
of 1-2 g of non-fish derived AO decreased serum triglycerides (TG) 15-20% compared to
baseline levels (r2=0.25, p < 0.05). In another study, AO has also been shown to significantly
increase high-density lipoprotein cholesterol (HDL-C) levels and to decrease low-density
lipoprotein cholesterol (LDL-C) levels from baseline (18).
We have previously compared the effects of FO or AO on mice. FO significantly reduced
serum TG, total cholesterol, and non-HDL-C (total cholesterol minus HDL-C) vs. soy oil (p <
0.01), but AO only reduced serum total cholesterol at the higher dose (10 g DHA/kg diet vs. 5 g
DHA/kg diet) (19). Subsequently, we determined that to equal the serum total cholesterol in the
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FO-fed mice, 3.5-5 times as much dietary DHA from AO needed to be fed (20). This may be due
to the fact that less DHA is incorporated into liver and adipose tissue lipids in AO-fed mice
compared to FO-fed mice (19,20). Therefore, AO appears less effective than fish oil at reducing
serum lipids in mice.
Non-marine derived yeast oil (YO) is comprised mainly of high EPA concentrations,
with very little DHA concentrations. YO is new on the market and little research has been
conducted on this particular PUFA source. YO is derived from the yeast strain, Yarrowia
lipolytica, which was modified to produce high EPA levels (34-60% EPA) (22). Published
literature on the effects of YO showed that serum TC and non-HDL levels in rats were both
significantly lower (p < 0.05) at all times points in the medium (488 mg/kg diet) and high (976
mg/kg diet) EPA YO groups compared to control (olive oil) (23).
There is a vast amount of evidence supporting the health benefits of fish oil (1,12,13,14),
which is high in both EPA and DHA, on CVD risk factors. However, the specific contributions
of EPA and DHA to these benefits are mostly unknown. Therefore, the objective of this study
was to examine non-marine sources of EPA or DHA vs. fish oil on body weight and serum
lipids.
II.

MATERIALS AND METHODS
A. Experimental Diets

Diets were based on a modified AIN-93G diet with soy isolate as the protein source
(Table 2). All diets consisted of 12% lipid by weight and the AO and YO containing diets were
formulated to provide the level of DHA and/or EPA provided by the 12% FO diet (7.03 g
DHA/kg diet and 12.64 g EPA/kg diet). The fatty acid composition of the oils is presented in
Table 3. All dietary ingredients, except algae and yeast oil, were purchased in purified form from
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Dyets, Inc. (Bethlehem, PA). The FO was produced from a menhaden fish source. The AO was
DHASCO, produced from Crypthecodinium Cohnii, and was provided by Martek Biosciences
Corporation (Columbia, MD). The YO was purchased from New Harvest (E. I. du Pont de
Nemours and Company, Wilmington, DE) and was manufactured from a genetically modified
strain of yeast, Yarowia lipolytica (22). Diets were flushed with nitrogen gas and stored at -20°C
prior to feeding.
B. Animal Feeding Study
All animal procedures were approved by the West Virginia University Animal Care and
Use Committee. The animal feeding study was performed at the Office of Laboratory Animal
Research at the Health Sciences Center on the West Virginia University campus located in
Morgantown, WV. Male ICR mice (n=100; 8 wks old) were obtained from Harlan, Inc.
(Madison, WI) and individually housed in cages with a 12 hr light/dark cycle (lights on from
0700 hr – 1900 hr). After a 7 day acclimation period to the control powdered diet, mice were
blocked by body weight and randomly assigned to one of five dietary treatment groups: SO, FO,
AO, YO, or AO+YO.
Mice had free access to the diets and water at all times and fresh diet was provided three
times per week to prevent oxidation and rancidity of the long chain fatty acids. Body weight was
measured once per week and feed intake was measured three times per week. Ten mice per diet
were euthanized by carbon dioxide asphyxia following 2 weeks of experimental diet
consumption after a 5 hr fast. Mice were bled by cardiac puncture and tissues including the liver,
and epididymal and retroperitoneal fat pads were collected, weighed by the same researcher, and
flash frozen within 10 minutes of euthanasia. Tissues were stored at -80°C until analysis. The
remaining ten mice per diet were euthanized and sampled following 4 weeks of experimental diet
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consumption after a 5 hr fst. Body fat index was calculated as: (epididymal fat pad weight +
retroperitoneal fat pad weight) / total body weight X 100.
C. Fatty Acid Analysis
Total fatty acids were extracted from the liver for fatty acid analysis according to a
modified method of Bligh and Dyers (24). Briefly, diced liver tissue (~0.5 g) was added to 5 mL
Tris/EDTA buffer. A 20 mL solution of chloroform:methanol:acetic acid (2:1:0.015, v/v/v) was
added. Samples were centrifuged (900 x g, 10°C, 10 min) and the bottom chloroform layer was
collected. A solution of 10 mL chloroform:methanol (4:1, v/v) was added to the samples and
centrifuged again (900 x g, 10°C, 10 min) and the bottom chloroform layer was collected.
The fatty acids were methylated using the method by Park and Goins (25). The extracted
lipids were dried under nitrogen gas in a 60°C water bath. A solution of 0.5M NaOH in methanol
was added, followed by the addition of 14% boron trifluoride. The samples were then incubated
in a water bath at 90°C for 30 min, then the fatty acid methyl esters were extracted in hexane.
The samples were transferred to a glass vial and stored at 4°C until analyzed by gas
chromatography at the University of Georgia (Athens, GA) as described previously (26).
Heptadecanoic acid (17:1) was used as an internal standard and fatty acids were identified using
retention times and peak area based on mixed fatty acid methyl ester standards (GLC-502, GLC484, GLC-87, GLC-455; Nu-Check Prep, Inc., Elysian, MN).
D. Serum Lipid and Lipoprotein Measurements
Blood was allowed to clot, then centrifuged for 20 minutes at 4°C at 2000 x g. Serum was
collected and frozen at -20°C until analysis for triglycerides, total cholesterol, and HDL
cholesterol using commercially available colorimetric kits (Wako Chemicals USA, Inc.)
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following the manufacturer’s protocol. To calculate non-HDL cholesterol, HDL cholesterol was
subtracted from total cholesterol.
E. RNA Isolation and Gene Expression
The relative liver mRNA expression of several genes involved in lipid metabolism
(HMG-CoA Reductase, LDL-Receptor, diglyceride acyltransferase (DGAT), ApoB100, acylCoA:cholesterol acyltransferase (ACAT)) were determined by real time RT-PCR as previous
described by Barnes et al. with slight modifications (27). Total RNA was extracted (50-75 grams
liver tissue) with TRIzol Reagent (Invitrogen, Carlsbad, CA) following the manufacturer’s
protocol. The RNA pellet was dissolved in nuclease-free, sterile water and quantified using a
NanoDrop 1000 spectrophotometer (Thermo Scientific, Waltham, MA). Total RNA (1μg) was
heat denatured (80°C for 3 min, then chilled on ice) and reverse transcribed using the iScript
cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, CA) following the manufacturer’s
protocol. Gene-specific primers were designed to span a splice-junction and amplify ~100 bp
segments (Table 4).
The final real-time reactions were run in triplicate in a reaction volume of 25 μL, which
contained 10 ng of reverse-transcribed RNA, 0.2 μg gene-specific primers, and 1 X SYBR Green
Supermix (Bio-Rad Laboratories). Reactions were performed in a C1000 iCycler Thermal Cycler
(Bio-Rad Laboratories) with an initial stage of 95°C for 3 min, followed by 40 cycles of 95°C for
15 sec and 60°C for 1 min. A melt curve was run to confirm the production of a single product.
Efficiency of amplification was determined using DART (28) and relative expression was
calculated using the ΔΔCT method accounting for gene-specific efficiencies (29) using acidic
ribosomal phosphoprotein (ARP) as the housekeeping gene.
F. Statistical Analysis
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An individual mouse was the experimental unit for all analyses (n = 100). Data was
analyzed by analysis of variance (ANOVA) using a fixed model testing the main effects of diet
and block within time period. Block x diet interactions were tested and all were found not to be
significant, therefore they were removed from the model. F-tests, least squares means, and
standard error of the mean (SEM) were calculated using the PROC MIXED procedure of SAS
(SAS Inst. Inc., Cary, NC). Means were separated by least significant difference test with P <
0.05 considered significant and with P < 0.10 considered as a trend.
III.

RESULTS
A. Feed Intake, Body Weight, and Tissue Weight

There were no significant differences among any of the diet treatments at any time points
of total average daily feed intake (TADFI), final body weight (FBW), retroperitoneal (RP)
adipose tissue weight, or epididymal (EPI) adipose tissue weight (Table 5). Consequently, there
were no significant differences in BFI between any of the diet treatments. However, there was a
trend at 2 weeks for AO+YO-fed mice to have a greater BFI compared to all other dietary
treatments. There was a trend at 2 weeks for SO-fed mice to have greater TADFI compared to all
other dietary treatments. There was a trend at 2 weeks for RP weight to be greater in the AO and
AO+YO-fed mice compared to all other dietary treatments (Table 5). At 2 weeks, FO and YOfed mice had significantly greater relative liver weights compared to SO-fed mice. At 4 weeks,
FO-fed mice had significantly greater relative liver weights compared to SO-fed mice (p < 0.05)
(Fig. 3).
B. Serum Lipids and Lipoproteins
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At 2 weeks, all dietary treatments, except YO-fed mice, had significantly lower serum
total cholesterol compared to SO-fed mice. At 4 weeks, all dietary treatments, except AO-fed
mice, had significantly lower serum total cholesterol compared to SO-fed mice (p < 0.05) (Fig.
4A). This reduction was due primarily to reductions in non-HDL cholesterol (p < 0.05) (Fig. 4B).
None of the diet treatments had significantly different HDL cholesterol levels compared to SOfed mice (Fig. 4C). However, at 2 weeks the AO-fed mice had significantly greater HDL
cholesterol levels compared to the FO and YO-fed mice, and at 4 weeks the AO-fed mice had
significantly greater HDL cholesterol levels compared to the FO, YO, and AO+YO –fed mice (p
< 0.05). The FO-fed mice had significantly lower serum TGs compared to the SO-fed mice at 2
weeks (p < 0.05), but not at 4 weeks (Fig. 4D). However, FO-fed mice had significantly lower
serum TGs at 4 weeks compared to YO-fed mice (p < 0.05).
C. Fatty Acid Analysis of the Liver
There were no significant differences among any of the dietary treatments in hepatic
incorporation of stearic acid (C18:0), arachidic acid (C20:0), eicosenoic acid (C20:1), and
eicosadienoic acid (C20:2) (Table 6). At 2 and 4 weeks, FO-fed mice had significantly greater
hepatic EPA (C20:5) and DHA (C22:6) concentrations than all other diet treatments (p < 0.05)
(Table 6). At 2 weeks, all diet treatments had significantly greater EPA concentrations than SOfed mice in the order of FO > AO+YO > YO > AO > SO. At 4 weeks, AO-fed mice did not
differ in EPA compared to SO-fed mice. YO and AO+YO-fed mice were similar in EPA, but still
less than FO-fed mice. At 2 and 4 weeks, all diet treatments had significantly greater DHA
concentrations than SO-fed mice. At 2 weeks, AO and AO+YO-fed mice were similar, greater
than YO-fed mice, but less than FO-fed mice. At 4 weeks, DHA was in the order of FO >
AO+YO > AO > YO > SO.
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At 2 and 4 weeks, FO and YO-fed mice had significantly greater docosapentaenoic acid
(C22:5) content compared to SO, AO, and AO+YO-fed mice. At weeks 2 and 4, SO-fed mice
had significantly greater arachidonic acid (ARA; C20:4), an omega-6 LC-PUFA, concentrations
than all other diet treatments. At weeks 2 and 4, FO-fed mice had significantly less linoleic acid
(C18:2), an omega-6 LC-PUFA, than all other diet treatments. At week 2, FO and AO+YO-fed
mice had significantly less α-linolenic acid (C18:3n-3), an omega-3 LC-PUFA, concentrations
than any other diet treatments. However, at week 4 there were no significant differences
between any of the diet treatments in α-linolenic acid concentration.
At week 2, SO-fed mice had significantly less SFA concentrations then all other diet
treatments. At week 4, FO-fed mice had significantly greater SFA concentrations than all other
diet treatments due to greater myristic acid (C14:0) and palmitic acid (C16:0). There were no
significant differences in PUFA concentration between any of the diet treatments at any time
points. At 2 weeks, SO-fed mice had significantly greater MUFA concentrations compared to FO
and AO+YO-fed mice. At 4 weeks, SO-fed mice had significantly greater MUFA concentrations
compared to FO, YO, and AO+YO-fed mice due to greater oleic acid (C18:1) content. FO-fed
mice had significantly greater palmitoleic acid (C16:1) content compared to all dietary
treatments at both 2 and 4 weeks.
At weeks 2 and 4, the FO-fed mice had significantly greater total omega-3 (n-3)
concentrations than any other diet treatments due to the greater EPA and DHA levels. At week 2,
SO-fed mice had significant greater omega-6 (n-6) concentrations than all other diet treatments.
At week 4, the SO and YO-fed mice had significantly greater n-6 concentrations than all other
diet treatments due to greater ARA, gamma-linolenic acid (GLA; C18:3n-6), and dihomogamma-linolenic acid (DGLA; C20:3n-6) concentrations. At both 2 and 4 weeks, FO-fed mice
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had significantly less n-6 concentrations compared to all other diet treatments. At weeks 2 and 4,
FO-fed mice had significantly greater omega-3 to omega-6 ratios (n-3:n-6) compared to all other
diet treatments due to high n-3 levels along with low n-6 levels.
D. mRNA Relative Expression of Selected Genes in the Liver
There were no significant differences between any of the diet treatments at any time points in
hepatic relative mRNA expression of the following genes: acyl-CoA:cholesterol acyltransferase
(ACAT), apolipoprotein B (ApoB100), diglyceride acyltransferase (DGAT), and low-density
lipoprotein receptor (LDLR) (Fig. 5A-D, respectively). However, at weeks 2 and 4, the FO-fed
mice had significantly less 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCR) expression
compared to the SO-fed mice (p < 0.05) (Fig. 5E). AO and AO+YO-fed mice had less (p < 0.05)
HMGCR expression compared to YO-fed mice, although it was not different from SO.
IV.

DISCUSSION

It has previously been reported that the n-3 LC-PUFAs, EPA and DHA, have been
associated with a decreased risk of CVD incidence (1). Mice in this study fed n-3 LC-PUFAs
did not reduce body weight, body fat index, or adipose tissue in the RP and EPI fat pad depots
(Table 5). Our results are contrary to other findings, but these differences could be due to
differences in study length (1 week to 7 weeks) or in dietary fat content (10.4% to 40% energy
from fat) (12,13,14). However, our results are similar to a study by Tou et al., in which SpragueDawley rats fed fish oil from a Menhaden source (12% diet from lipid) had no significant
differences between any diet groups (corn, flaxseed, krill, salmon, or tuna oils) in RP adipose
tissue weight. Rats fed a menhaden-diet had similar liver weights (g/100 g body weight)
compared to corn oil-fed rats (30). This is contradictory to the results in our study where FO-fed

27

mice had significantly greater relative liver weights compared to all other dietary treatments
(Table 5). Increased liver weight can be associated with many negative health consequences such
as hepatic steatosis, non-alcoholic liver disease, cirrhosis, and liver cancer (31). A possible cause
of increased hepatic weight can be excess lipid storage in the liver. However, in our study this
was not the case because there were no significant differences in hepatic total lipid content at 2
weeks and SO-fed mice had significantly greater hepatic total lipid content at 4 weeks compared
to all other diet treatments (Bush M and Barnes KM, unpublished results). There were also no
significant differences in TG content of the liver between any of the diet treatments at any time
point (Bush M and Barnes KM, unpublished results). Therefore, the increased liver weights in
the FO-fed mice cannot be attributed to hepatic total lipid or TG content. Possible explanations
for the differences in liver weight could be due to hepatic protein, fluid, or glycogen content.
It has previously been reported that fish oil supplementation decreases serum TG
concentration (12,13,14). In support of this, mice in our study fed fish oil lowered all fractions of
plasma lipids, and only FO reduced serum TGs (Fig. 4). There are three possible mechanisms in
which omega-3 PUFAs may lower serum TGs: 1) reduced substrate (i.e. fatty acids) availability,
which could be secondary to an increase in β-oxidation, decreased free fatty acid delivery to the
liver or decreased hepatic fatty acids synthesis, 2) increased phospholipid synthesis, or 3)
decreased activity of triglyceride-synthesizing enzymes (DGAT) (32). In our study, the first
mechanism is unlikely since there was similar TG and lipid content in the liver among the
different dietary treatments. In terms of the second mechanism, we did not measure phospholipid
synthesis. As for the final mechanism, we found no change in DGAT mRNA expression,
however we did not measure the activity of this enzyme.
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YO, alone and in combination with AO, reduced total and non-HDL cholesterol similar
to FO at 4 wks. At 2 weeks, AO also reduced total and non-HDL cholesterol. Reductions in total
cholesterol were primarily due to reductions in non-HDL cholesterol (Fig. 4). Therefore, it
appears that the reductions in serum total and non-HDL cholesterol may be attributed to the EPA
content of the diet. In support of these findings, a previous study by MacKenzie et al. found that
rats fed yeast oil in medium and high-EPA groups (98 mg EPA/kg and 488 mg EPA/kg body
weight per day, respectively) had significantly lower total and non-HDL cholesterol compared to
a control diet (olive oil) (23). In our study, AO-fed mice had similar serum HDL levels as SO-fed
mice, but these levels were numerically greater than all other dietary treatments at both 2 and 4
weeks. Therefore, it appears that the increases in serum HDL-cholesterol may be due to the DHA
content of the diet. In a previous study by our lab, mice fed algae oil resulted in a significant
decrease in total cholesterol compared to SO-fed mice after 2 weeks of supplementation, but
higher doses of algae oil were needed in order to significantly reduce total cholesterol at 4 weeks
(20).
It has previously been reported that HMG-CoA reductase mRNA expression is downregulated with n-3 LC-PUFAs supplementation in both in vivo (33) and in vitro studies (34,35).
Similarly in our study, FO-fed mice significantly down-regulated HMG-CoA reductase
expression compared to SO-fed mice at both time points (Fig 5E). In a rat cell culture study by
Kaur et al., DHA was more effective at down-regulating HMG-CoA reductase expression than
EPA (76% vs. 53%, respectively) compared with oleic acid (P < 0.05) (33). This is similar to the
results found in our study evidenced by the AO-fed mice having significantly lower HMG-CoA
reductase expression compared with YO-fed mice (P < 0.05) (Fig 5E). These results are
important because HMG-CoA reductase is an important point for the regulation of cholesterol
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synthesis. HMG-CoA reductase is the rate limiting enzyme in cholesterol synthesis, reducing 3hydroxy-3-methylgluaryl CoA (HMG-CoA) to mevalonate (6). Therefore, suppressed HMGCoA reductase levels in FO-fed mice could be a possible explanation for significantly decreased
total cholesterol levels compared to SO-fed mice. However, this explanation may not hold true
for AO and YO-fed mice. Even though YO-fed mice had numerically greater hepatic HMGCR
mRNA expression compared to all dietary treatments at both 2 and 4 weeks, YO-fed mice had
numerically decreased serum TC levels at 2 weeks and significantly lower TC at 4 weeks
compared to SO-fed mice. Similarly, AO-fed mice had numerically lower hepatic HMGCR
mRNA expression compared to SO and YO-fed mice at 4 weeks, but AO-fed mice had similar
serum TC levels compared to SO-fed mice.
FO-fed mice had numerically lower ACAT mRNA levels than SO-fed mice (Fig. 5A).
These results are supported by previous work in rats where fish oil-fed rats had significantly
lower hepatic ACAT mRNA expression compared to rats fed corn oil (36,37). We detected no
significant differences in LDL-receptor mRNA expression between any of the diet treatments
(Fig. 5D). LDL is the primary carrier of cholesterol in the blood, from which 60% is taken up by
LDL receptors in the liver, adrenals, and various other tissues. The number and activity of LDL
receptors is a determinant of the level of LDL-C in the blood (6). Interestingly however, FO,
YO, and AO+YO-fed mice had significantly lower serum non-HDL levels compared to the SOfed mice (Fig. 4B). There were also no significant differences in DGAT (Figure 5C) or
ApoB100 (Fig. 5B) mRNA expression between any of the diet treatments. These findings are
consistent with two previous studies in rats fed a fish oil diet compared to rats fed control diets
(corn oil and sunflower oil, respectively) (37,38). Our data indicates that the changes in serum
lipids in omega-3 fatty acid-fed rodents may not be the result of altered transcription.
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Because the liver is the major site of n-3 LC-PUFA synthesis and metabolism, it is
important to analyze the PUFA deposition in the liver from different dietary sources. Increasing
tissue omega-3 LC-PUFAs can employ beneficial health effects by influencing 1) eicosanoid
pathways, which alters inflammation, 2) modulation of molecules and enzymes involved with
various signaling pathways and cell functions, 3) cell membrane phospholipids and fluidity, and
4) direct effects on gene expression (39). In our study, mice fed AO, alone and in combination
with YO, had significantly lower ARA (C20:4) deposition in the liver compared to SO, FO, and
YO-fed mice. Similar to a previous study (30), FO-fed mice had significantly lower ARA
deposition in the liver compared to SO-fed mice (Table 6). These findings may have important
clinical implications because decreased ARA reduces the synthesis of pro-inflammatory series-2
eicosanoids (41).
At both time points, FO-fed mice had significantly greater hepatic EPA (C20:5) and
DHA (C22:6) concentrations than all other diet treatments (Table 6). This is consistent with our
findings in which FO-fed mice had significantly greater EPA and DHA incorporation into
skeletal muscle and EPI adipose tissue compared to all other diet treatments at 4 weeks. FO-fed
mice also had significantly less DHA excretion in the feces compared to AO and AO+YO-fed
mice at 2 and 4 weeks. However, there were no significant differences between FO, AO+YO,
and YO-fed mice in the excretion of EPA in the feces (Ketz JS and Barnes KM, unpublished
results). These results are further supported by a previous study at West Virginia University
where greater doses of algae oil were required in order to obtain equal liver and adipose tissue
DHA concentrations as mice fed fish oil (20). This could account for the lesser response to algae
and yeast oils. AO-fed mice may have had greater hepatic EPA incorporation at 2 weeks
compared to SO-fed mice due to the liver’s ability to retro-convert DHA to EPA. YO-fed mice
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may have had significantly greater hepatic DHA incorporation at 2 and 4 weeks compared to
SO-fed mice due to the liver’s ability to convert EPA to DHA.
At week 2, SO-fed mice had significantly less hepatic SFA concentrations than all other
diet treatments. At week 4, FO-fed mice had significantly greater hepatic SFA concentrations
than all other diet treatments due to greater hepatic myristic acid (C14:0) and palmitic acid
(C16:0) levels. These differences are consistant with the differences in the fatty acid profile of
the oils themselves. There were no significant differences in hepatic PUFA concentration
between any of the diet treatments at any time points. At 2 weeks, SO-fed mice had significantly
greater hepatic MUFA concentrations compared to FO and AO+YO-fed mice. At 4 weeks, SOfed mice had significantly greater hepatic MUFA concentrations compared to FO, YO, and
AO+YO-fed mice due to greater oleic acid (C18:1) content. SO-fed mice may have had the
greatest concentrations of liver MUFA because the soy oil and algae oil had greater amounts of
oleic acid (20% and 25%, respectively) compared to the fish oil and yeast oil (8% and 5%,
respectively) (Table 3). Moderate dietary MUFA consumption has been found to be
cardioprotective in promoting optimal blood lipids, improving blood pressure and insulin
sensitivity, and regulating blood glucose levels (40).
In our study, FO-fed mice had significantly greater hepatic omega-3 PUFA
concentrations at both time points compared to all other diet treatments (Table 6). FO-fed mice
also had significantly less hepatic omega-6 PUFA concentrations at both time points compared
to all other diet treatments (Table 6). These results are consistent with findings from previous
studies (20,35). Therefore, at both time points FO-fed mice had significantly greater hepatic
omega-3 to omega-6 ratios compared to all other diet treatments (Table 6). The ratio of omega-6
to omega-3 essential fatty acids has important implications because linoleic acid (omega-6) and
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alpha-linolenic acid (omega-3) compete for the same rate limiting enzyme in the synthesis of
LC-PUFAs, Δ6-desaturase. A high omega-6 to omega-3 ratio and a low omega-3 to omega-6
ratio, which is typical in Western diets, promote the progression of many diseases such as CVD,
cancer, inflammatory diseases, and autoimmune diseases. There are many discrepancies in the
literature as to the optimal omega-6 to omega-3 ratio in humans, ranging from 1:1 to 4:1,
depending on the individual and the disease condition (41). The omega-6 to omega-3 ratios in
our diets were as follows: SO; 7.03 > AO; 3.61 > YO; 2.95 > AO+YO; 1.80 > FO; 0.40.
SUMMARY AND CONCLUSION
The present study evaluated alternative sources of omega-3 LC-PUFAs on serum lipids
and lipoproteins, hepatic fatty acid composition, and hepatic gene expression. Our study is novel
because we evaluated the effects of non-marine sources versus marine sources of omega-3 LCPUFAs. There are few studies that assess the effects of YO on health and cardiovascular
parameters.
Our study showed that FO supplementation may be more beneficial at lowering serum
lipids compared to non-marine sources. It appears that EPA is more beneficial at lowering
cholesterol since YO-fed mice, but not AO-fed mice, lowered serum cholesterol and NHDLC.
FO was also the only diet to significantly lower serum TGs. Mice fed a diet consisting of FO
were also more efficient at incorporating EPA and DHA into the liver as well as down-regulating
hepatic HMGCR mRNA expression. However, FO also had the highest omega-3 to omega-6
ratio.
These results are significant because HMGCR is the rate limiting enzyme in cholesterol
synthesis. The ratio of omega-6 to omega-3 essential fatty acids has important implications
because linoleic acid (omega-6) and alpha-linolenic acid (omega-3) compete for the same rate
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limiting enzyme in the synthesis of LC-PUFAs, Δ6-desaturase. However, a high omega-6 to
omega-3 ratio, which is typical in Western diets, promotes the progression of many diseases such
as CVD, cancer, inflammatory diseases, and autoimmune diseases.
Future research into the dietary consumption of marine vs. non-marine sources of omega3 LC-PUFAs in the prevention of CVD is a promising area of contribution. Further research
would benefit from comparing different sources of marine origin vs. non-marine origin and
studying a variety of hepatic genes involved in lipid metabolism.
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Figure 1: Chemical structures of docosahexaenoic acid (DHA), eicosapentaenoic acid
(EPA), and arachidonic acid (ARA). Molecules are oriented with methyl (omega) terminal on
the reader's left (39).
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Figure 2: Cholesterol Synthesis Pathway (7)
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Table 1. Types of Marine vs. Non-Marine Sources of Omega-3 Fatty Acids (1)

Marine Sources Non-Marine Sources
Tuna
Flaxseed*
Sardines
Walnuts*
Salmon
Soybean Oil**
Mackerel
Canola Oil*
Menhaden **
Hempseed*
Herring
Butternuts*
Rainbow Trout
Algae Oil **
Halibut
Yeast Oil **
Cod
Haddock
Catfish
Flounder/Sole
Oyster
Lobster
Alaskan King Crab
Shrimp
Scallop

* Plant sources, typically high in ALA
** Sources used in our study
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Table 2. Ingredient Composition of the Experimental Diets Fed to Mice

Ingredient (g/kg) 1
Isolated Soy Protein
Cornstarch
Dextronized Cornstarch
Sucrose
Cellulose
Soy Oil
Fish Oil 2
Algae Oil 3
Yeast Oil 4
AIN-93G Mineral Mix
AIN-93G Vitamin Mix
L-Cysteine
L-Methionine
Choline Bitartrate

1

SO

FO

AO

YO

AO + YO

200
345.42
132
100
50
120
35
10
2.54
2.54
2.5

200
345.42
132
100
50
120
35
10
2.54
2.54
2.5

200
345.42
132
100
50
92.7
27.3
35
10
2.54
2.54
2.5

200
345.42
132
100
50
97.79
22.21
35
10
2.54
2.54
2.5

200
345.42
132
100
50
70.49
27.3
22.21
35
10
2.54
2.54
2.5

All ingredients except algae and yeast oils were obtained from Dyets, Inc. (Bethlehem, PA).

Algae oil was produced by Martek Biosciences Corporation (Columbia, MD). Yeast oil was
produced by New Harvest (E. I. du Pont de Nemours and Company, Wilmington, DE).
2

Fish oil contained 10.54% EPA + 5.86% DHA

3

Algae oil contained 0.47% EPA + 25.76% DHA

4

Yeast oil contained 56.94% EPA + 0.08% DHA
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Table 3. Dietary Fatty Acid Composition of the Oils.
Fatty Acids1
(mg FA/g oil)

1

Treatment Oils
SO

FO

AO

YO

C14:0

0.06

15.15

19.38

0.13

C16:0

10.00

25.76

12.92

3.63

C16:1

0.08

16.69

3.51

0.55

C18:0

3.30

3.34

0.80

2.39

C18:1

19.75

8.39

25.12

5.19

C18:2

57.06

1.66

1.59

19.98

C18:3

8.16

1.85

0.04

1.35

C20:5

0.01

10.54

0.47

56.81

C22:6

ND3

5.86

25.79

0.08

Other

1.59

10.76

10.37

9.89

Fatty acids from the oils were analyzed by gas chromatography and expressed as a percent of

total fatty acids (mg FA/g oil).
2

SO = soy oil; FO = fish oil; AO = algae oil; YO = yeast oil

3

ND = none detected
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Table 4. Details of Primers Used for Real-time Reverse-Transcription PCR

Gene 1

GenBank
Accession No.

Forward Primer

Reverse Primer

Product
Size (bp)

HMGCR

NM_008255

GGGTCTGGACGAAGATGTGT

TGCTCAATGTCCATGCTGAT

93

LDLR

NM_010700

AACCTGGAAGGCAGCTACAA

CGGTTGGTGAAGAGCAGATAG

122

DGAT

NM_010046

GAATATCCCCGTGCACAAGT

GGAAGAAGGCTGAGGTCAAA

118

ApoB100

NM_009693

TCAACCTTGCAGTTTCTGGA

CACAGTGTTGAAGTGTTCCTTTG

105

ACAT-1

NM_144784

CCCATCACCATCTCAGTGAA

GGTCTTGAGCTTTGGCACTT

124

ARP

NM_007475

GCGACCTGGAAGTCCAACTA

GCTCCCACAATGAAGCATTT

77

1

HMGCR = 3-hydroxy-3-methyl-glutaryl-CoA reductase, LDLR = low-density lipoprotein receptor,

DGAT = diglyceride acyltransferase, ApoB100 = apolipoproteinB 100, ACAT = acetyl-Coenzyme A
acetyltransferase-1, ARP = acidic ribosomal phosphoprotein, housekeeping gene
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Figure 3. Relative Liver Weights (g/gbw). Data are presented as mean + SEM. Different
letters within week indicate significant differences between treatments (p < 0.05).
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Table 5. Effect of Dietary Treatment on Feed Intake, Body Weight, and Tissue Weight
Diet1
Measurement2 Week
2
FBW (g)

4
2

BFI (%)

4
2

TADFI (g)

4
2

RP Weight(g)

4
2

EPI Weight
(g)
1

4

SO

FO

AO

YO

AO+YO

SEM

P-Value

37.21

37.62

37.73

35.79

37.98

0.608

0.109

39.86

40.08

39.68

40.15

40.92

1.019

0.928

2.94

2.54

2.94

2.52

3.18

0.198

0.098

4.68

3.39

3.93

3.63

4.07

0.445

0.316

6.25

6.05

5.17

5.80

5.43

0.282

0.065

5.75

5.67

5.91

5.76

5.10

0.296

0.362

0.25

0.21

0.29

0.22

0.29

0.0248

0.098

0.66

0.28

0.38

0.35

0.41

0.122

0.271

0.85

0.74

0.83

0.69

0.93

0.065

0.119

1.23

1.09

1.19

1.12

1.28

0.131

0.845

SO = soy oil diet; FO = fish oil diet; AO = algae oil diet; YO = yeast oil diet; AO+YO = algae

oil plus yeast oil diet; SEM = standard error of the mean.
2

FBW = final body weight; BFI (%) = body fat index (%); TADFI = total average daily feed

intake; RP Weight = retroperitoneal tissue weight; EPI Weight = epididymal tissue weight.
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Figure 4. Effect of Dietary Treatment on Serum Lipids.
A. Total Cholesterol, B. HDL Cholesterol, C. Triglycerides, D. Non-HDL Cholesterol. Data are presented as means + SEM. Different
letters within week indicate significant differences between treatments (p < 0.05).
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Table 6: Effect of Dietary Treatment on the Fatty Acid Profile of the Liver
Diet2

Fatty Acid1

Week

SO

FO

AO

YO

AO+YO

SEM

P-Value

2

0.37b

0.68a

0.48b

0.46b

0.39b

0.065

0.015

4

0.38c

0.67a

0.55b

0.37c

0.46bc

0.041

<0.0001

2

23.88d

28.71a

26.38bc

24.89cd

27.91ab

0.648

<0.0001

4

22.68b

30.26a

26.41ab

25.79b

24.15b

1.348

0.005

2

1.12b

2.63a

1.01b

1.09b

1.10b

0.142

<0.0001

4

1.51b

2.90a

1.30b

1.29b

1.17b

0.162

<0.0001

2

9.03

11.61

9.74

11.36

10.86

0.710

0.068

4

8.31c

12.00ab

9.61bc

10.05abc

13.02a

1.055

0.023

2

14.68a

8.98c

13.39ab

12.22ab

11.94b

0.879

0.001

4

16.36a

8.55d

14.54ab

11.13cd

11.81bc

1.055

<0.0001

2

29.31a

10.74d

25.88b

26.97ab

22.66c

0.910

<0.0001

4

28.57a

7.93c

25.74ab

28.05a

23.20b

1.052

<0.0001

2

1.37a

0.85b

1.07ab

1.16ab

0.88b

0.114

0.015

4

4.13

0.68

1.22

1.17

0.94

1.192

0.251

2

0.22ab

0.29a

0.12b

0.15b

0.092b

0.044

0.020

4

0.19ab

0.30a

0.11b

0.06b

0.07b

0.040

0.0004

2

0.34

0.34

0.31

0.36

0.30

0.103

0.992

4

0.21

0.33

0.31

0.23

0.21

0.050

0.302

2

0.38

0.18

0.31

0.28

0.23

0.074

0.417

4

0.28

0.10

0.23

0.26

0.14

0.069

0.302

C14:0

C16:0

C16:1

C18:0

C18:1

C18:2

C18:3n-3

C18:3n-6

C20:0

C20:1
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Diet2

Fatty Acid1

Week

SO

FO

AO

YO

AO+YO

SEM

P-Value

2

0.37

0.37

0.31

0.33

0.26

0.078

0.398

4

0.19

0.30

0.24

0.27

0.14

0.069

0.507

2

1.31

1.09

1.55

1.36

1.36

0.284

0.850

4

1.30a

0.40b

1.51a

1.41a

1.28a

1.275

<0.0001

2

11.26a

5.20c

4.49cd

7.29b

3.74d

0.458

<0.0001

4

9.75a

5.49b

3.57c

6.21b

3.14c

0.494

<0.0001

2

0.34e

5.60a

1.97d

3.40c

4.34b

0.221

<0.0001

4

1.08c

6.50a

2.08c

4.06b

4.47b

0.472

<0.0001

2

0.13c

1.55a

0.25c

1.24a

0.77b

0.129

<0.0001

4

0.06c

1.84a

0.13c

1.82a

0.13b

0.162

0.162

2

5.92d

21.53a

12.95b

7.73c

13.54b

0.573

<0.0001

4

5.14e

21.82a

12.63c

7.87d

14.90b

0.655

<0.0001

2

33.61c

41.34a

36.91b

37.08b

39.45ab

1.111

0.0003

4

31.58c

43.26a

36.88b

36.43b

37.85b

1.652

0.0006

2

16.17a

11.79c

14.70ab

13.59abc

13.27bc

0.916

0.024

4

18.16a

11.55c

16.06ab

12.68c

13.12bc

1.140

0.001

2

50.21

46.88

48.39

49.33

47.28

1.010

0.133

4

50.26

45.19

47.05

50.89

49.03

1.625

0.102

2

10.03e

30.05a

17.26c

13.53d

20.52b

0.907

<0.0001

4

11.30d

32.37a

16.32c

15.61cd

21.55b

1.735

<0.0001

2

39.82a

16.67e

30.82c

35.46b

26.50d

1.402

<0.0001

C20:2

C20:3n-6

C20:4

C20:5

C22:5

C22:6

SFA

MUFA

PUFA

n-3

n-6
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4

38.77a

12.52c

30.49b

35.02a

27.34b

1.459

<0.0001

2

0.28d

1.89a

0.57bc

0.38cd

0.80b

0.085

<0.0001

4

0.34b

2.88a

0.54b

0.46b

0.80b

0.191

<0.0001

n-3:n-6

1

Fatty acids from the liver were analyzed by gas chromatography and expressed as a percent of

total fatty acids. SFA = saturated fatty acids; MUFA = monounsaturated fatty acids; PUFA =
polyunsaturated fatty acids; n3 = omega-3 fatty acids, n6 = omega 6 fatty acids, n3:n6 = omega-3
fatty acid to omega-6 fatty acid ratio.
2

SO = soy oil diet; FO = fish oil diet; AO = algae oil diet; YO = yeast oil diet; AO+YO = algae

oil plus yeast oil diet; SEM = standard error of the mean.
abcde

Different letters within a row represent significant differences within week (p < 0.05).
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Figure 5. Effect of Dietary Treatment on mRNA Relative Gene Expression in the Liver – A. acyl-CoA:cholesterol acyltransferase
(ACAT), B. apolipoprotein B (ApoB100); C. diglyceride acyltransferase (DGAT); D. low-density lipoprotein receptor (LDLR). E. 3-hydroxy3-methyl-glutaryl-CoA reductase (HMGCR). Data are presented as means + SEM. Different letters within week indicate significant differences
between treatments (p < 0.05).
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